Exelixis (NASDAQ: EXEL) announced that the European Commission (EC) has approved COTELLIC™ (cobimetinib) for use in combination with vemurafenib for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE